# PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

> **NCT04022785** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 43 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
- Myelodysplastic/Myeloproliferative Neoplasm
- Myeloproliferative Neoplasm

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** BRD4 Inhibitor PLX51107

## Key facts

- **NCT ID:** NCT04022785
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-09
- **Primary completion:** 2022-10-24
- **Final completion:** 2022-10-24
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2022-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04022785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04022785, "PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04022785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*